Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB

Eur Respir J. 2021 Jan 5;57(1):2001796. doi: 10.1183/13993003.01796-2020. Print 2021 Jan.

Silke Feuerriegel^{1

2}, Thomas A Kohl^{1

2}, Christian Utpatel^{1

2}, Sönke Andres³, Florian P Maurer^{3

4}, Jan Heyckendorf^{2

5

6}, Agathe Jouet⁷, Nelly Badalato⁷, Lynda Foray⁸, Rashidatu Fouad Kamara⁸, Osman S Conteh⁹, Philip Supply^{10

11}, Stefan Niemann^{1

2

11}

¹ Molecular and Experimental Mycobacteriology, Research Centre Borstel, Borstel, Germany.
² German Centre for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel, Borstel, Germany.
³ National and WHO Supranational Reference Centre for Mycobacteria, Research Centre Borstel, Borstel, Germany.
⁴ Institute of Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
⁵ Clinical Infectious Diseases, Research Centre Borstel, Borstel, Germany.
⁶ International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
⁷ Genoscreen, Campus de l'Institut Pasteur de Lille, Lille, France.
⁸ National Tuberculosis Control Programme, Ministry of Health and Sanitation, Freetown, Sierra Leone.
⁹ National Reference Laboratory, Lakka Government Hospital, Freetown, Sierra Leone.
¹⁰ Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
¹¹ P. Supply and S. Niemann contributed equally to the study.

No abstract available

Publication types